Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Dec 31;16(6):2900-2904.
doi: 10.21037/jgo-2025-751. Epub 2025 Dec 5.

Potential of regorafenib in late-line treatment for refractory advanced gastric cancer

Chikara Kunisaki  1
Affiliations
Editorial

Potential of regorafenib in late-line treatment for refractory advanced gastric cancer

Chikara Kunisaki. J Gastrointest Oncol. .
No abstract available

Keywords: Advanced gastric cancer (AGC); chemotherapy; regorafenib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-2025-751/coif). The author has no conflicts of interest to declare.

Comment on

  • INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.
    Pavlakis N, Shitara K, Sjoquist K, Martin A, Jaworski A, Tebbutt N, Bang YJ, Alcindor T, O'Callaghan C, Strickland A, Rha SY, Lee KW, Kim JS, Bai LY, Hara H, Oh DY, Yip S, Zalcberg J, Price T, Simes J, Goldstein D. Pavlakis N, et al. J Clin Oncol. 2025 Feb;43(4):453-463. doi: 10.1200/JCO.24.00055. Epub 2024 Oct 4. J Clin Oncol. 2025. PMID: 39365958 Clinical Trial.

References

    1. Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2025. 7th ed. Tokyo: Kanehara & Co., Ltd.; 2025.
    1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97. 10.1016/S0140-6736(10)61121-X - DOI - PubMed
    1. Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 2023;402:2197-208. 10.1016/S0140-6736(23)02033-0 - DOI - PubMed
    1. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2023;401:1655-68. 10.1016/S0140-6736(23)00620-7 - DOI - PubMed
    1. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 2023;29:2133-41. 10.1038/s41591-023-02465-7 - DOI - PMC - PubMed